COPENHAGEN, Denmark, 02 December 2021 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma"), a Danish company powered by cannabinoids is hereby proud to announce that that there was broad political support for the proposal to make the current Pilot Programme to a permanent scheme. The scheme was adopted exclusively with yes votes (102-0).
It has been agreed that the Pilot Programme will be extended by a further four years with regard to the possibility for doctors to prescribe medical cannabis to patients. In addition, it has been agreed that the Pilot Programme will be made permanent with regard to the companies' ability to manufacture cannabis for medical use. The purpose of making the manufacturing part permanent is to create peace of mind and security for the investments made in the industry.
- We are very pleased that the scheme for the manufacturing of medical cannabis has been made permanent, as it is in principle a safeguarding of our business basis and our existence. And then it actually means something when the proposal is voted through with 102-0, because it shows us that we are dealing with an area that politicians, authorities and NGOs really want to be successful, says Jeppe Krog Rasmussen, CEO of DanCann Pharma.
The new agreement is good news for the entire Danish medical cannabis industry and the ecosystem, as it will probably attract further investment and stimulate the positive wave that is currently going on in the industry and which will help make Denmark a leading nation in the medical cannabis field.
- We are engaged in a lot of exciting and ambitious activities, and even though we probably expected a positive statement from the politicians, there is of course always a little uncertainty. Now it is official that the industry - and we as a company - can calm down and start creating further investments, development and earnings, states Jeppe Krog Rasmussen.
With the decision to make Danish manufacturing of medical cannabis permanent after the expiry of the current Pilot Programme, Denmark formally continues its ambition to become a leading player in medical cannabis with ambitions to serve both the domestic market and international markets.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
About DanCann Pharma
DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com
For further information, please contact:
Jeppe Krog Rasmussen, CEO